BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD. Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Stock
Equities
688621
CNE100005139
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.62 CNY | -0.16% |
|
-2.52% | -27.43% |
| Sales 2024 * | 1.26B 174M | Sales 2025 * | 1.65B 228M | Capitalization | 5.67B 783M |
|---|---|---|---|---|---|
| Net income 2024 * | 277M 38.25M | Net income 2025 * | 388M 53.58M | EV / Sales 2024 * | 4.5 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.43 x |
| P/E ratio 2024 * |
20.4
x | P/E ratio 2025 * |
12.8
x | Employees | 1,126 |
| Yield 2024 * |
1.36% | Yield 2025 * |
1.8% | Free-Float | 52.15% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.16% | ||
| 1 week | -2.52% | ||
| Current month | -10.17% | ||
| 1 month | -10.91% | ||
| 3 months | -16.28% | ||
| 6 months | -23.49% | ||
| Current year | -27.43% |
1 week
50.04
52.60
1 month
50.0459.40
Current year
50.0472.48
1 year
50.0475.78
3 years
50.04134.29
5 years
50.04134.29
10 years
50.04134.29
| Managers | Title | Age | Since |
|---|---|---|---|
Yu Jing Liu
CEO | Chief Executive Officer | 42 | 09-02-28 |
Ling Yang Zhao
DFI | Director of Finance/CFO | 36 | 20-03-20 |
Ming Juan Wang
CTO | Chief Tech/Sci/R&D Officer | 48 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qian Li
CHM | Chairman | 43 | 09-03-08 |
Qiao Chen
BRD | Director/Board Member | 44 | 20-03-20 |
Zhuang Kun He
BRD | Director/Board Member | 52 | 20-03-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 50.62 | -0.16% | 890,320 |
| 24-05-23 | 50.7 | -2.71% | 1,213,063 |
| 24-05-22 | 52.11 | +0.66% | 793,483 |
| 24-05-21 | 51.77 | -0.54% | 1,157,872 |
| 24-05-20 | 52.05 | +0.23% | 1,307,467 |
End-of-day quote Shanghai S.E., May 23, 2024
More quotes
Beijing Sun Novo Pharmaceutical Research Co Ltd is a China-based company that provides research and development outsourcing services for pharmaceutical companies. The Company's main businesses include comprehensive research and development services in generic drug development, consistency evaluation and innovative drug development. Its services mainly include pharmaceutical research, clinical trials and biological analysis. Pharmaceutical research services include raw materials and preparation process research, quality standards and stability research, etc. Clinical trial services include phase I-IV clinical trial research, Bioequivalency (BE) test research. Biological analysis services include the use of mass spectrometry analysis platform, immunoassay platform, cell analysis platform, molecular biology analysis platform for method development, method validation, biological sample detection research, etc. The Company mainly conducts its businesses in the domestic market.
Calendar
2024-08-15
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
50.62
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.43% | 783M | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +45.66% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- 688621 Stock
